About us
Anteo Diagnostics (ASX:ADO) is a surface coating company with a proprietary platform for the rapid design of superior surfaces for the biotechnology, diagnostics and pharmaceutical industries. Our lead Mix&GoTM family of protein binding agents is gaining traction with a wide spectrum of clients in the in vitro diagnostics industry including bead manufacturers, test developers, test manufacturers and life science companies.
The company evolved from Bio-Layer Corporation Ltd (ASX:BLS), an Australian material science company, established in 1999 as privately held Polymerat and listed on the ASX through a reverse acquisition by SSH Medical (ASX:SSH) in October of 2005. The company’s initial emphasis on surface chemistry and proteomics tools, turned to greater focus on immunoassays and related applications used in diagnostics. In 2008, the Company was renamed Anteo Diagnostics, derived from the latin root for "anticipate, prevent, precede", reflecting the Company’s approach to diagnostics opportunities. Mix&GoTM technology has been extensively validated over subsequent years resulting in commercial licences to Life Technologies, Bangs Laboratories and Merck KGaA.
The company's principal facility comprises over 1000 m2 of state-of-the art laboratory space in Brisbane, Australia. Anteo currently employs approximately 20 people.
Our core competencies in surface coating technology come to the fore in rapid assay development and enhancement on different assay platforms resulting in demonstrable improvements in performance, cost and manufacturing.
Our mission is to become a successful …
Ours is a tight, collaborative, team oriented culture reflecting our regional community with members from many different countries. We are totally customer focused on creating solutions that are meet your exact requirements and reduce your time to market.
